American Society For Gastrointestinal Endoscopy

TissueCypher Test Shows Promise in Identifying Barrett's Esophagus Patients at Risk for Esophageal Cancer

23 days ago

• New data presented at DDW 2025 demonstrates TissueCypher's ability to detect missed neoplasia in non-dysplastic Barrett's esophagus patients, potentially enabling earlier intervention. • Castle Biosciences' precision medicine test aims to shift Barrett's esophagus management from "wait and see" to personalized surveillance strategies that could prevent progression to esophageal cancer. • Multiple educational sessions at DDW 2025 feature leading gastroenterology experts discussing clinical applications of the tissue systems pathology test for improved risk stratification in Barrett's esophagus.

Recursion's REC-4881 Shows 30% Polyp Reduction in FAP Patients in Phase 1b/2 Trial

a month ago

• Recursion's MEK 1/2 inhibitor REC-4881 demonstrated a median reduction of over 30% in total polyp burden after 12 weeks in patients with familial adenomatous polyposis (FAP), a rare hereditary colorectal cancer syndrome. • The preliminary data from the TUPELO trial will be presented as a late-breaking oral presentation at Digestive Disease Week 2025, highlighting potential first-in-disease treatment for approximately 50,000 FAP patients across major markets. • REC-4881, which has received Fast Track and Orphan Drug designations from the FDA, was identified through Recursion's AI-powered platform analyzing cellular models of APC gene loss—the root cause of FAP.

Critical Drug Shortages Persist in 2024 Despite Overall Decline in Supply Disruptions

5 months ago

• U.S. drug shortages decreased to 277 cases by September 2024, yet half of all shortages continue to extend beyond two years, affecting critical medications including ADHD treatments and chemotherapy agents. • Essential medications facing significant supply constraints include morphine, fentanyl, methotrexate, carboplatin, and diabetes medications like Semaglutide, impacting patient care across multiple therapeutic areas. • Supply chain disruptions, manufacturing delays, and increased demand remain key factors contributing to ongoing medication shortages, creating persistent challenges for healthcare providers and patients.

Updated Colonoscopy Guidelines Reshape Quality Metrics as Family Physician Procedures Decline

5 months ago

• The American College of Gastroenterology and American Society for Gastrointestinal Endoscopy released updated colonoscopy quality guidelines in 2024, introducing new metrics including bowel preparation adequacy rate. • Family physician-performed colonoscopies have significantly decreased from 11.32% in 2016 to 6.73% in 2021, with procedures now concentrating among specialists. • Type 2 diabetes significantly impacts colorectal cancer outcomes, with diabetic patients showing reduced 5-year survival rates of 82.23% compared to 94.40% in non-diabetic patients.

Schizophrenia Treatment Targeting Cholinergic Receptors Receives FDA Approval

6 months ago

• The FDA has approved a novel treatment for schizophrenia, marking the first in decades to target cholinergic receptors instead of dopamine receptors. • The treatment involves xanomeline and trospium chloride capsules, offering a new mechanism of action for adults with schizophrenia. • This development addresses a critical need for alternative treatment options in schizophrenia management, potentially improving patient outcomes.

FDA Grants Dual Approval for Amivantamab in Non-Small Cell Lung Cancer Treatment

8 months ago

• The FDA has issued two separate approvals for amivantamab, marking a significant advancement in the treatment options available for patients with non-small cell lung cancer. • Dr. Joshua K. Sabari from NYU Langone Health highlights amivantamab's potential as an exciting new therapeutic option for NSCLC patients, emphasizing its clinical importance.